| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/30/2009 | US20090110662 Modification of biological targeting groups for the treatment of cancer |
| 04/30/2009 | US20090110661 Novel Gene Therapy Approach For Treating The Metabolic Disorder Obesity |
| 04/30/2009 | US20090110657 Skin care compositions |
| 04/30/2009 | US20090110656 Skin cooling composition |
| 04/30/2009 | US20090110655 Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis |
| 04/30/2009 | US20090110649 Antipruritic cosmetic and dermatological preparations |
| 04/30/2009 | US20090110644 Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
| 04/30/2009 | US20090110632 Biological materials and uses thereof |
| 04/30/2009 | DE202008005433U1 Kauzusammensetzung Kauzusammensetzung |
| 04/30/2009 | DE102008031556A1 Composition, useful e.g. as shampoo, hair coloring agent, lotion and gel or cream, comprises e.g. tyrosine and/or its derivative, protein hydrolysate, adenosine-triphosphate and a substance comprising riboflavin and lyxoflavin |
| 04/30/2009 | DE102007051693A1 Pharmaceutical preparation, useful e.g. as layer tablet, comprises estrogen or estrogen/gestagen combination with carriers, where the estrogen component is added in different concentrations in the tablet phase and layers of the preparation |
| 04/30/2009 | DE102007047737A1 Piperidin- und Piperazinderivate Piperidine and piperazine derivatives |
| 04/30/2009 | DE102005056558B4 Kombinationspräparate enthaltend physiologische Zellmembran-Bestandteile Combination products containing physiological cell membrane components |
| 04/30/2009 | DE10128250B4 Neue Glykolipidderivate, Verfahren zu deren Herstellung und diese enthaltende Mittel Glykolipidderivate new, processes for their preparation and compositions comprising them |
| 04/30/2009 | CA2711839A1 Method of treatment with potentised stereoisomer of glutamate |
| 04/30/2009 | CA2711824A1 A method and medicament for pain management |
| 04/30/2009 | CA2704100A1 Compositions and methods for treating fibroproliferative disorders |
| 04/30/2009 | CA2704098A1 Compositions and methods for enhancing immune response |
| 04/30/2009 | CA2704052A1 Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 04/30/2009 | CA2704049A1 Means and methods for counteracting muscle disorders |
| 04/30/2009 | CA2704013A1 Spiro-ring compound and use thereof for medical purposes |
| 04/30/2009 | CA2704008A1 New tetracyclic compounds |
| 04/30/2009 | CA2703797A1 Amine derivative having npy y5 receptor antagonist activity and use thereof |
| 04/30/2009 | CA2703793A1 Oxadiazolidinedione compound |
| 04/30/2009 | CA2703653A1 Pyridine and pyrazine derivatives -083 |
| 04/30/2009 | CA2703647A1 Process for preparing o-desmethylvenlafaxine |
| 04/30/2009 | CA2703645A1 Composition for reducing the level of glucose, malondialdehyde-modified ldl, homocysteine and/or c-reactive protein in blood |
| 04/30/2009 | CA2703635A1 Diarylhydantoin compounds as androgen receptor modulators |
| 04/30/2009 | CA2703593A1 4,4-disubstituted piperidines |
| 04/30/2009 | CA2703494A1 Inhibitor of pai-1 production |
| 04/30/2009 | CA2703489A1 Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| 04/30/2009 | CA2703479A1 Therapeutic substituted lactams |
| 04/30/2009 | CA2703477A1 Tropane compounds |
| 04/30/2009 | CA2703475A1 Process for the preparation of macrolide antibacterial agents |
| 04/30/2009 | CA2703472A1 Methods for treating substance dependence |
| 04/30/2009 | CA2703471A1 Pyrazinyl amide t-type calcium channel antagonists |
| 04/30/2009 | CA2703465A1 Synthesis and crystalline forms of cb-1 antagonist/inverse agonist |
| 04/30/2009 | CA2703461A1 Compounds of 2,3-dihydro-benzofuran |
| 04/30/2009 | CA2703458A1 Phenylpyrrolidine compounds |
| 04/30/2009 | CA2703453A1 Indoline compounds |
| 04/30/2009 | CA2703441A1 An amorphous form of an anti-inflammatory compound |
| 04/30/2009 | CA2703365A1 Nifedipine-containing press coated tablet and method of preparing the same |
| 04/30/2009 | CA2703338A1 Method of preventing adverse effects by glp-1 |
| 04/30/2009 | CA2703299A1 Anti-microbial composition |
| 04/30/2009 | CA2703290A1 New non-peptide derivatives as bradykinin b1 antagonists |
| 04/30/2009 | CA2703234A1 Delivery of active agents |
| 04/30/2009 | CA2703230A1 Novel crystalline forms |
| 04/30/2009 | CA2703224A1 Pharmaceutical formulation of clavulanic acid |
| 04/30/2009 | CA2703203A1 Bicyclic heterocycle derivatives and methods of use thereof |
| 04/30/2009 | CA2703179A1 Liposomal vancomycin formulations |
| 04/30/2009 | CA2703163A1 (1,4-diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone ligands for nicotinic acetylcholine receptors, useful for the treatment of disease |
| 04/30/2009 | CA2703158A1 Composition for treatment of joint disease |
| 04/30/2009 | CA2703157A1 Amino arylsulfonamide compounds and their use as 5-ht6 ligands |
| 04/30/2009 | CA2703152A1 Lipoic acid pellet composition |
| 04/30/2009 | CA2703149A1 Idarubicin for the treatment of lymphoma in a dog |
| 04/30/2009 | CA2703138A1 Purine derivatives useful as pi3 kinase inhibitors |
| 04/30/2009 | CA2703106A1 Azolecarboxamide derivatives as trka inhibitors |
| 04/30/2009 | CA2703080A1 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors |
| 04/30/2009 | CA2703054A1 Hydrated crystalline esters of camptothecin for the treatment of cancer |
| 04/30/2009 | CA2703044A1 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
| 04/30/2009 | CA2702984A1 Compositions and methods for treatment of diabetic retinopathy |
| 04/30/2009 | CA2702976A1 2-aminooxazole derivatives as trpv1 antagonists useful for treating pain |
| 04/30/2009 | CA2702974A1 Amino 1,2,4-triazole derivatives as modulators of mglur5 |
| 04/30/2009 | CA2702962A1 Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor |
| 04/30/2009 | CA2702800A1 Long acting injectable formulations |
| 04/30/2009 | CA2702786A1 Novel imidazole derivatives |
| 04/30/2009 | CA2702772A1 Diazepane compounds which modulate the cb2 receptor |
| 04/30/2009 | CA2702510A1 Use of norgestimate as a selective inhibitor of trpc3, trpc6 and trpc7 ion channels |
| 04/30/2009 | CA2702506A1 Anti-malarial pharmaceutical composition |
| 04/30/2009 | CA2702447A1 New phenyl-substituted piperazino-dihydrothienopyrimidines |
| 04/30/2009 | CA2702126A1 Heterocycle amide t-type calcium channel antagonists |
| 04/30/2009 | CA2701956A1 Combination therapy |
| 04/30/2009 | CA2701747A1 Novel imidazole derivatives |
| 04/30/2009 | CA2701723A1 Novel crystalline salts of montelukast |
| 04/30/2009 | CA2701594A1 Heterocycle phenyl amide t-type calcium channel antagonists |
| 04/30/2009 | CA2701286A1 Carbacephem .beta.-lactam antibiotics |
| 04/30/2009 | CA2701276A1 Thienopyrimidiene derivatives as pi3k inhibitors |
| 04/30/2009 | CA2701275A1 Novel kinase inhibitors |
| 04/30/2009 | CA2700915A1 Cyclohexeneamide derivatives and their use as trpv1 antagonist |
| 04/30/2009 | CA2700430A1 Influenza virus haemagglutinin-specific monoclonal antibodies |
| 04/30/2009 | CA2700210A1 Condensed compounds with activity at estrogen receptors |
| 04/30/2009 | CA2699805A1 Treatment regime for proliferative disorders |
| 04/30/2009 | CA2609172A1 Immunotherapy compositions for use with targeted therapy in the treatment of cancer |
| 04/29/2009 | EP2053409A1 Specific markers for metabolic syndrome |
| 04/29/2009 | EP2053393A1 Pladienolide target molecule, compound capable of binding to the target molecule, and screening method for the compound |
| 04/29/2009 | EP2053067A1 Poly and copoly (N-vinylamide)s and their use in capillary electrophoresis |
| 04/29/2009 | EP2053050A1 Dihydrochalcone similar to aspalathin and method for its manufacture |
| 04/29/2009 | EP2053043A1 Crystalline salt of montelukast |
| 04/29/2009 | EP2053042A1 Pyridine compounds for the treatment of prostaglandin mediated diseases |
| 04/29/2009 | EP2053041A2 1,3,5-Trisubstituted 2(1H)-pyridones as AMPA receptor inhibitors useful for the treatment of eg Parkinson's disease |
| 04/29/2009 | EP2053040A1 Pregabalin intermediates and process for preparing them and Pregabalin |
| 04/29/2009 | EP2053039A1 Novel crystal of 5-aminolevulinic acid phosphate and process for production thereof |
| 04/29/2009 | EP2053038A1 Aminoalcohol derivative and immunosuppressant containing the same as an active ingredient |
| 04/29/2009 | EP2053033A1 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors |
| 04/29/2009 | EP2052751A2 Use of high citrate dialysate |
| 04/29/2009 | EP2052732A1 Antioxidant composition containing component originating in the bark of tree belonging to the genus acacia |
| 04/29/2009 | EP2052731A1 Composition for preventing and/or treating itching containing component originating in the bark of tree belonging to the genusacacia |
| 04/29/2009 | EP2052730A1 Composition for preventing and/or treating tumor containing component originating in the bark of tree belonging to the genus acacia |
| 04/29/2009 | EP2052729A1 Antiobesity composition containing component originating in the bark of tree belonging to the genus acacia |
| 04/29/2009 | EP2052728A1 Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia |